ObesityGLaDNCT07001553
Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study
An observational study of Obesity and Type 2 Diabetes Mellitus (T2DM), run by Australian Catholic University at 1 site in Australia.
Trial summary
An observational study of those who have been prescribed a GLP-1 agonist therapy (yet to commence), for either weight or diabetes management, and are willing to complete dietary records and questionnaires of behaviour and psychosocial health. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obesity, Type 2 Diabetes Mellitus (T2DM)
- How many people
- 37 participants
- Where
- 1 siteAustralia
- Study dates
- 28 May 2025to 7 Jan 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Individuals living in Australia who are intending to commence a GLP-1 prescription
Who may be able to join
- Aged 18+ years old
- Intending to commence a prescription for a GLP-1 agonist (may be dual agonist, i.e. Ozempic, Trulicity, Monjaro, or Saxenda) medication, with no use in the previous 6 months
- The primary reason for commencing the medication will be for diabetes or weight management
- Willing to participate in dietary recall and questionnaires
Who cannot join
- Aged under 18 years,
- used a GLP-1 agonist medication in the previous 6 months,
- unwilling or unable to provide dietary recalls
- non-English speaking.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Understanding the Dietary Adjustments Following GLP-1 Agonist Treatment: The GLaD Feasibility Study
An observational study of those who have been prescribed a GLP-1 agonist therapy (yet to commence), for either weight or diabetes management, and are willing to complete dietary records and questionnaires of behaviour and psychosocial health.
Read the detailed description
Forty individuals (20 for weight management, 20 for diabetes management) living in Australia who have been prescribed a GLP-1 agonist (no previous prescription or no use in the previous 6 months) will be recruited to participate over the initial 3 months of their treatment. Assessments will occur remotely (online) at baseline, 2 weeks, 1 month and 3 months. Optional body composition assessments will be provided at baseline and 3 months for those based in Melbourne, Australia.
- Conditions
- Obesity, Type 2 Diabetes Mellitus (T2DM)
- Keywords
- dietary behaviours, psychosocial health
- Medical subject headings
- Obesity, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Weight management | Prescribed GLP-1 agonist therapy primarily for weight management | |
| Type 2 diabetes | Prescribed GLP-1 agonist therapy primarily for glycemic management |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of recruitment
The rate of recruitment and the retention rate of participants completing the dietary assessment measures.
Measured: 4 months
Secondary outcomes (3)
Energy intake
Assessed using Intake24 records for at least 2 days per timepoint
Measured: baseline, 2 weeks, 1 month, 3 months
Medication symptomology
Incidence of self-reported side effects
Measured: baseline, 1 month, 3 months
Medication use
Dosage
Measured: baseline, 1 month, 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2025
- Study start28 May 2025
- Primary completion7 Jan 2026
- Study completion7 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 37 participants (actual)
Sponsor and investigators
- Lead sponsor
- Australian Catholic University
- Sponsor type
- University, hospital or other
- Collaborators
- St Vincent's Hospital Melbourne, The University of Queensland
- Responsible party
- Sponsor
- Investigators
- Evelyn B Parr, PhD, Principal investigator, Australian Catholic University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07001553
- Sponsor's protocol ID
- 2025-4090H
- Acronym
- GLaD
- Status last verified
- Feb 2026
- First submitted
- 22 May 2025
- Last updated
- 2 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data that support the findings of this study will be available from the corresponding author for a period of 36 months from publication, upon reasonable request for academic use. The data will not be made publically available, as it contains information that could compromise research participant consent.
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Understanding the Dietary Adjustments Following GLP-1 Agonist Treatment: The GLaD Feasibility Study
- ClinicalTrials.gov ID
- NCT07001553
- Acronym / sponsor ID
- GLaD / 2025-4090H
- Conditions
- Obesity, Type 2 Diabetes Mellitus (T2DM)
- Keywords
- dietary behaviours, psychosocial health
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 37 participants (actual)
- Lead sponsor
- Australian Catholic UniversityUniversity, hospital or other
- Collaborators
- St Vincent's Hospital Melbourne, The University of Queensland
- Study start
- 28 May 2025 (actual)
- Primary completion
- 7 Jan 2026 (actual)
- Study completion
- 7 Jan 2026 (actual)
- First posted
- 3 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An observational study of those who have been prescribed a GLP-1 agonist therapy (yet to commence), for either weight or diabetes management, and are willing to complete dietary records and questionnaires of behaviour and psychosocial health.
Detailed description
Forty individuals (20 for weight management, 20 for diabetes management) living in Australia who have been prescribed a GLP-1 agonist (no previous prescription or no use in the previous 6 months) will be recruited to participate over the initial 3 months of their treatment. Assessments will occur remotely (online) at baseline, 2 weeks, 1 month and 3 months. Optional body composition assessments will be provided at baseline and 3 months for those based in Melbourne, Australia.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Weight management | – | –Prescribed GLP-1 agonist therapy primarily for weight management |
| Type 2 diabetes | – | –Prescribed GLP-1 agonist therapy primarily for glycemic management |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Individuals living in Australia who are intending to commence a GLP-1 prescription
Key inclusion criteria (4 listed)
- Aged 18+ years old
- Intending to commence a prescription for a GLP-1 agonist (may be dual agonist, i.e. Ozempic, Trulicity, Monjaro, or Saxenda) medication, with no use in the previous 6 months
- The primary reason for commencing the medication will be for diabetes or weight management
- Willing to participate in dietary recall and questionnaires
Key exclusion criteria (4 listed)
- Aged under 18 years,
- used a GLP-1 agonist medication in the previous 6 months,
- unwilling or unable to provide dietary recalls
- non-English speaking.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Feasibility of recruitment
Time frame: 4 months
The rate of recruitment and the retention rate of participants completing the dietary assessment measures.
3 secondary outcomes
Energy intake
Time frame: baseline, 2 weeks, 1 month, 3 months
Medication symptomology
Time frame: baseline, 1 month, 3 months
Medication use
Time frame: baseline, 1 month, 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
- Individual participant dataSharing planned: Yes. The data that support the findings of this study will be available from the corresponding author for a period of 36 months from publication, upon reasonable request for academic use. The data will not be made publically available, as it contains information that could compromise research participant consent.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Evelyn B Parr, PhD principal investigator
Australian Catholic University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity and Type 2 Diabetes Mellitus (T2DM), run by Australian Catholic University at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of recruitment (time frame: 4 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.